Publications by authors named "A S Nadas"
Article Synopsis
- The study focuses on the HIV-1 envelope (Env) protein, crucial for developing effective vaccines, and explores how the signal peptide (SP) affects its antigenicity (ability to trigger immune response) and immunogenicity (ability to induce an immune response).
- Researchers compared the Env proteins from two different HIV-1 isolates, assessing their natural forms and chimeras with swapped SPs, using various methods to evaluate their antigenicity and responses in mice.
- Results showed that swapping SPs influenced the antibodies' binding, with some chimeras showing improved immunogenicity, while the inclusion of DNA vaccines reduced the effectiveness of the wild-type proteins in generating a strong immune response.
Introduction: Neutralizing antibodies (Abs) are one of the immune components required to protect against viral infections. However, developing vaccines capable of eliciting neutralizing Abs effective against a broad array of HIV-1 isolates has been an arduous challenge.
Objective: This study sought to test vaccines aimed to induce Abs against neutralizing epitopes at the V1V2 apex of HIV-1 envelope (Env).
A fraction of patients with COVID-19 develops severe disease requiring hospitalization, while the majority, including high-risk individuals, experience mild symptoms. Severe disease has been associated with higher levels of antibodies and inflammatory cytokines but often among patients with diverse demographics and comorbidity status. This study evaluated hospitalized vs.
View Article and Find Full Text PDFHIV-1 envelope (Env) is a trimer of gp120-gp41 heterodimers, synthesized from a precursor gp160 that contains an ER-targeting signal peptide (SP) at its amino-terminus. Each trimer is swathed by ~90 N-linked glycans, comprising complex-type and oligomannose-type glycans, which play an important role in determining virus sensitivity to neutralizing antibodies. We previously examined the effects of single point SP mutations on Env properties and functions.
View Article and Find Full Text PDFBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people globally. Virus infection requires the receptor-binding domain (RBD) of the spike protein. Although studies have demonstrated anti-spike and -RBD antibodies to be protective in animal models, and convalescent plasma as a promising therapeutic option, little is known about immunoglobulin isotypes capable of blocking infection.
View Article and Find Full Text PDF